A considerable number of patients undergoing allogeneic hematopoietic SCT (HSCT) develop post-transplant complications requiring intensive care unit (ICU) treatment. Whereas the indications and the outcome of ICU admission are well known, the risk factors leading to ICU admission are less well understood. We performed a retrospective single-center study on 250 consecutive HSCT patients analyzing the indications, risk factors and outcome of ICU admission. Of these 250 patients, 33 (13%) were admitted to the ICU. The most common indications for admission to the ICU were pulmonary complications (11, 33%), sepsis (8, 24%), neurological disorders (6, 18%) and cardiovascular problems (2, 6%). Acute GvHD and HLA mismatch were the only significant risk factors for ICU admission in multivariate analysis. Among patients admitted to the ICU, the number of organ failures correlated negatively with survival. Twenty-one (64%) patients died during the ICU stay and the 6-month mortality was 85% (27 out of 33). SAPS II score underestimated the mortality rate. In conclusion, acute GvHD and HLA mismatch were identified as risk factors for ICU admission following allogeneic HSCT. Both, short-and long-term survival of patients admitted to the ICU remains dismal and depends on the number of organ failures.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) significantly improves the overall survival in a variety of hematologic disorders. 1 However, despite recent advances, HSCT continues to be associated with a high risk for complications, such as respiratory failure, visceral organ injury, systemic infections and GvHD. All these complications lead to considerable transplant-related morbidity and mortality (TRM). A substantial number of patients has to be transferred to the intensive care unit (ICU) either during the early transplant period or later during follow-up. 2, 3 The likelihood of admission to the ICU varies considerably among HSCT centers resulting in a wide range of admission rates in the published literature, overall approximately 16% (range: 5% to more than 55%). 2, 3 These differences can be explained to a large extent by the different criteria for ICU admission among different hospitals. Even though overall survival for both HSCT as well as ICU treatment have substantially improved during the last decade, all reported studies clearly show that ICU admission after allogeneic HSCT is still associated with a very poor prognosis. [2] [3] [4] [5] Several factors such as need for invasive respiratory support or catecholamines are associated with a poorer survival during the ICU stay. 2, 3 Although numerous studies have addressed the factors associated with the poor survival of HSCT patients admitted to the ICU, little is known about the risk factors leading to ICU admission. 2 The aim of the current study was to analyze the high-risk population of HSCT recipients admitted to the ICU, in particular, the risk factors and indications for ICU admission, and their outcome.
PATIENTS AND METHODS
This retrospective single-center study analyzed 250 consecutive patients receiving allogeneic HSCT between 1998 and 2007 at the University Hospital of Zü rich (Switzerland). The main parameters measured were the risk factors and indications for ICU admission, 6-month mortality and overall survival. The decision to transfer a patient to the ICU was always made with the close collaboration of the transplant and the ICU teams. Septic patients were often treated in the SCT unit until organ support was mandatory. Beside severe infection needing organ support, isolated respiratory problems, neurological disturbances and the need for cardiovascular support were the main indications for ICU transfer. All patients consented for retrospective data analysis at the time of transplantation, which was approved by the local ethical committee. Baseline characteristics included sex, age, underlying disease, conditioning regimen, stem cell source, HLA-, ABO blood group-and gender-match between patients and donors, acute and chronic GvHD, CMV-risk constellation and survival of the cohort were collected for all 250 HSCT recipients. In the ICU group (n ¼ 33), the clinical charts were reviewed at the time of admission to the ICU and additional parameters were assessed including the time from transplantation to ICU-admission, the reason for ICU-admission, simplified Acute Physiology Score (SAPS II), renal function and need for renal replacement therapy, liver failure, mechanical ventilation, vasoactive drugs, duration of the ICU stay and ICU mortality. Acute and chronic GvHD were classified according to standard criteria.
Statistical analysis
Data were reported as proportions, means ( ± s.d.) or medians with ranges. Variables were compared in patients admitted to the ICU or not by the Mann-Whitney U-tests or w 2 tests as appropriate. The ICU survival was assessed using the Kaplan-Meier estimator and compared by the log-rank test. Risk factors for the admission to the ICU were analyzed by multiple logistic regression analysis. Risk factors analyzed included age, gender, underlying disease, transplant characteristics such as year of transplant, donor type and HLA match, ABO barrier, donor-recipient gender match, conditioning regimen, stem cell source and early post-transplant characteristics such as the presence and grade of acute GvHD. In patients admitted to the ICU, mortality was related to a simple organ failure score including the need for catecholamines, mechanical ventilation and renal replacement therapy. All reported P-values are two-sided, and Po0.05 was considered to be significant.
RESULTS

Patient characteristics
During the study period, 250 patients underwent allogeneic HSCT and 33 (13%) were admitted to ICU. The baseline characteristics of ICU and non-ICU patients are outlined in Table 1 . The median age of the whole population was 43 years (range 17-67) and the main indications for allogeneic HSCT were AML (117, 47%), CML (57, 23%), ALL (29, 11%) and lymphoma (30, 12%). The remainder of patients was transplanted for a variety of hematological disorders (17, 7%). The conditioning regimens were Cy/TBI ± other drugs (113, 45%), Bu/Cy±other drugs (48, 19%) and reduced intensity conditioning regimens (83, 33%) including Flu/Bu/ATG (68, 82%), Flu (Fludarabine)/TBI-2 (8, 10%), Flu/Melphalan/ATG (antithymocyte globulin) (6, 7%) and Flu/Cy (1, 1%). Five patients with severe aplastic anemia received Cy/ATG as conditioning regimen (2%) and one patient received high-dose melphalan for relapsed myeloma. One patient received melphalan as conditioning regimen and another patient received a second transplant without conditioning because of primary graft failure. The stem cell source was peripheral blood (134, 54%), BM (113, 45%) or cord blood (3, 1%). There were no significant differences between gender and gender mismatches, age at HSCT, underlying disease, conditioning regimen and stem cell source between the groups with and without ICU admission.
Risk factors for ICU admission
In univariate analysis, patients admitted to the ICU had significantly more often HLA mismatches (24% vs 8% P ¼ 0.009), transplants from unrelated donors (52% vs 26%, P ¼ 0.003) and acute GvHD grade II-IV (61% vs 15%, Po0.001). Acute GvHD occurred in the vast majority of patients before the ICU transfer (26/27, 96%). In multivariate logistic regression, the risk for ICU admission was significantly associated with acute GvHD grade II-IV (odds ratio: 8.7, 95% confidence interval (CI): 3.2-23.3, Po0.001) and HLA mismatches (odds ratio: 5.2, 95% CI: 1.2-23.5, P ¼ 0.031). In contrast, the stem cell source, donor relation, age of the patient, gender, ABO mismatch as well as conditioning and TBI were not associated with an increased risk for ICU admission.
Indications for ICU admissions and duration of ICU hospitalization The most common indications for admission to the ICU were pulmonary complications (11, 33%), sepsis (8, 24%), neurological disorders (6, 18%) and cardiovascular problems (2, 6%). Whereas the group of pulmonary complications consisted mainly of infection, bleeding and acute respiratory distress syndrome, neurologic disorders were bleeding, uncontrolled seizures and soporific state due to therapy. The median time from HSCT to ICU admission was 72 days (range 7-870) and the median duration of the ICU stay 3 days (0-57). One patient was transferred to the ICU 7 days before HSCT because of cardiovascular problems. He received the transplant in the ICU, but died 3 days after transplantation because of multiorgan failure. Two patients were transferred to the ICU on day 0 after myeloablative conditioning. One patient was transferred because of a transfusion-related acute lung injury during conditioning and transplanted with a doubleunit of umbilical cord blood in the ICU, but died because of an uncontrollable shock. The second patient had an anaphylactic drug reaction during conditioning and received a BMT in the ICU. He was transferred back to the SCT unit 1 day after transplantation and continues to be alive and in long-term remission of his CML. Twelve patients were transferred until day 30 after transplantation (36%) with a median time until ICU transfer of 6 days (-7 to 19). The remaining 21 patients (64%) were transferred beyond day 30 with a median time of 121 days (35-870) after HSCT. There were no differences in the duration of ICU stay (P ¼ 0.179), the indications for ICU transfer (0.199) and the ICU survival (P ¼ 0.653) in patients admitted early or late after transplantation to the ICU. Likewise, there were no differences in treatmentrelated mortality, ICU admission and mortality rates in the observed time period (Table 2) . 
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Outcome of HSCT recipients in the ICU Figure 1 shows the cumulative survival probability of the ICU and non-ICU group. Patients not admitted to the ICU had a clearly better overall survival with a 1-year survival probability of 85% (95% CI: 79-90%) as compared with 28% (95% CI: 13-44%) in patients admitted to the ICU (Po0.001). ICU patients often developed organ failure defined by the need for mechanical ventilation, catecholamines and renal replacement therapy. The majority of patients had respiratory failure requiring mechanical ventilation (21, 64%). Fourteen patients required catecholamine support (42%), and nine patients required renal replacement therapy (27%). Sixteen patients experienced multiorgan failure with at least two organs involved (48%). The mortality rate of patients admitted to the ICU was high. Of all 33 patients, 21 patients died during the ICU stay (64%). Patients with multiorgan failure had a higher ICU mortality (94% vs 29%, Po0.001). However, 6 out of 12 patients discharged from the ICU died within the first 100 days after discharge and the median survival time after discharge of all ICU survivors was 119 days (4-2917).
The main cause of death in the non-ICU group was relapse/ progression (81%) as compared with sepsis/infection (29%) and respiratory complications (23%) in the ICU group. Only 19% of the patients in the ICU group died from relapse/progression. Acute GvHD, the relation between donor and recipient, the age of the recipient, the underlying diagnosis, the conditioning regimen, CMV status and the stem cell source did not significantly influence survival in the ICU. Eleven patients (33%) had positive blood cultures directly before admission to the ICU or during the ICU stay. Patients with positive blood cultures had a slightly longer duration of ICU hospitalization (median 8.5 vs 2.5 days). However, this did not reach statistical significance (P ¼ 0.675). In addition, overall survival was similar in patients with or without positive blood cultures (P ¼ 0.504). Likewise, the SAPS II and the SOFA score did not reliably predict the survival in this group of patients (P ¼ 0.694 and P ¼ 0.312, respectively).
DISCUSSION
This retrospective study describes in more detail a population of patients admitted to the ICU and analyzes risk factors for their ICU admission. It shows that acute GvHD and HLA mismatches are the main risk factors associated with ICU referral after allogeneic HSCT. The outcome of patients admitted to the ICU remains dismal and depends on the number of organ failures.
Patients after allogeneic HSCT are at high risk for complications, which may or may not be transplant related, but eventually can lead to ICU admission. Although the main reasons for ICU admittance are well known, 2 there are insufficient data regarding the impact of HSCT-specific factors contributing to the occurrence these complications. The most important general indications for ICU admissions are respiratory failures, including pneumonia, diffuse alveolar hemorrhage and acute respiratory distress syndrome, requiring non-invasive or invasive mechanical ventilation, sepsis, cardiac dysfunction, in particular arrhythmias, neurologic disorders and gastrointestinal bleedings. 2, 3 Many of these may directly be related to the occurrence of acute GvHD. Indeed, in the current analysis, acute GvHD was a strong predictor of ICU admission and GvHD occurred in most patients before ICU admission. In contrast to other publications, 6, 7 TBI and conditioning were not associated with a higher risk for ICU admission. In multivariate analysis, the risk for ICU admission was eightfold higher in patients with acute GvHD as compared with those without. HLA disparity was the other major risk factor for ICU admission. The independent association of these two factors with ICU admission might be explained by the more profound immunosuppression of patients receiving HLA mismatched transplants and consequently leading to an a priori higher risk of ICU admission even in the absence of active GvHD. Thus, factors specifically related to allogeneic transplantation are major contributors to ICU admission.
In the current study, our overall admission rate was relatively low as compared with other reports (13%), in which the ICU admission rates ranged from less than 5% to more than 55%.
2,3
The relatively low ICU admission rate in this study might be explained by a late referral to the ICU as many patients especially with infectious problems were managed in the stem cell unit, which is equipped to provide intermediate care. Among the different studies, the wide range reflects several factors including patient selection, the center's facility and experience of the transplant unit to cope with severely ill patients, the decade of the transplant and the complex decision process of the ICU referral involving both transplant and ICU physicians. It is, however, almost impossible to standardize procedures for an ICU transfer among centers, because of different equipment and facilities on SCT units, thus prospective multicenter trials are difficult to perform in this area. In contrast, our single-center study has the advantage that standard procedures were more or less uniform during the reported period leading to less additional influencing factors. The weakness of the study, however, is its retrospective design and the relatively low number of patients admitted to the ICU.
Once the patient is admitted to the ICU, several prognostic factors are known from previous studies to be associated with an increased mortality: allogeneic compared with autologous HSCT, 8, 9 stem cell source, 4 time after transplantation, 10, 11 intubation and mechanical ventilation, 4, 12 hemodynamic instability, 13 increased patient age and prolonged duration of the ICU stay. 2, 13 Not surprisingly, there are data showing a correlation between the number of organ system failures and inferior outcome. 5, 14 In a recent study by Bird et al., GvHD was among a variety of other parameters significantly associated with in-hospital mortality; however, after multivariate analysis, invasive mechanical ventilation and failure of more than two organ systems were the only independent predictors. 15 In our study, only the latter factor revealed to be statistically significant. Patients with no or only one organ dysfunction had a higher chance of being discharged from the ICU, but the overall survival even after discharge remained poor. Interestingly, in contrast to predicting the risk for ICU admission transplant-related factors such as GvHD and HLA mismatch had no influence on the ICU mortality in our study. Risk factors for ICU admission and survival after allogeneic HSCT R Benz et al
Prognostic scores such as SAPS II or APACHE II and III are widely used in the ICU setting. However, these scores have not been validated in patients with allogeneic HSCT. Indeed, the SAPS II score underestimated the ICU mortality in our study population, which is in line with several other single-center or multicenter studies. 2, 4, 5, [15] [16] [17] [18] Even the largest study analyzing patients with HSCT or intensive chemotherapy demonstrated an underestimation of the actual mortality rates by conventional ICU scores. 16 SOFA score with cutoff values used by Gilli et al. 5 was not predicitive for ICU outcome either.
In conclusion, this study demonstrated that a considerable number of patients after allogeneic HSCT has to be transferred to the ICU and this remains associated with poor outcome. Risk factors for ICU admission are acute GvHD grade II-IV, and HLA mismatch. Although the overall outcome in this patient group is unfavorable, survival is better in patients without organ failure or with single-organ failure.
